Referenced MDPDA clinical resources in Nephrology, with transparent evidence and review metadata.
A UK clinical reference for detecting and confirming chronic kidney disease, interpreting eGFR and albuminuria, assessing progression, reducing cardiovascular and renal risk and recognising indications for specialist nephrology assessment.
An international clinical guide to acute kidney injury, covering creatinine and urine-output criteria, volume assessment, nephrotoxins, obstruction, electrolyte complications and indications for renal replacement therapy.
An international emergency guide to hyperkalaemia, including confirmation, ECG assessment, membrane stabilisation, intracellular shift therapies, potassium removal and recurrence prevention.
An international guide to hypotonic hyponatraemia, covering emergency hypertonic saline, diagnostic classification, SIADH, fluid balance and prevention of osmotic demyelination.
A practical guide to adult nephrotic syndrome, including quantification of proteinuria, cause-directed workup, oedema management, thrombosis and infection risk, and biopsy referral.
An international guide to suspected glomerulonephritis, including urine microscopy, proteinuria, complement and serology, kidney biopsy and emergency management of rapidly progressive disease.
An international guide to renal and ureteric stones, covering emergency red flags, analgesia, imaging, infected obstruction, expulsive management and metabolic prevention.
A practical guide to persistent proteinuria and haematuria, covering repeat testing, albumin quantification, glomerular clues, urological cancer risk and referral thresholds.
An international critical-care guide to when dialysis or continuous kidney replacement therapy should be considered in acute kidney injury, emphasising complications and clinical trajectory.
A professional guide to CKD-mineral and bone disorder, including interpretation of calcium, phosphate and PTH, vitamin D, vascular calcification and treatment principles.
An international guide to diabetic kidney disease, integrating eGFR and albuminuria, renin-angiotensin blockade, SGLT2 inhibition, mineralocorticoid receptor therapy and cardiovascular risk.
